viewZynerba Pharmaceuticals

Zynerba Pharmaceuticals shares sink after unsuccessful trial of cannabis-based skin patch

The company will shift its focus to ZYN002, a treatment for epilepsy

ZYN001 delivers THC through a transdermal patch

Zynerba Pharmaceuticals Inc (NASADAQ:ZYNE) shares sank following an unsuccessful early-stage trial of ZYN001, its cannabinoid skin patch.

ZYN001 is designed to deliver THC through a transdermal patch.

In the placebo-controlled Phase 1 study, a total of 60 volunteers participated in the study with differently formulated patches and varying wear times.

While there were no serious adverse effects detected, the skin patch did not achieve its goal of target THC levels in the blood.

The company, which develops cannabis-based therapies for rare neuropsychiatric disorders, will shift its focus to ZYN002 Fragile X syndrome, a treatment for epilepsy.

Shares of the Pennsylvania-based company fell more than 20% to US$7.64 in Thursday pre-market trading.

Quick facts: Zynerba Pharmaceuticals

Price: 3.42 USD

Market: NASDAQ
Market Cap: $100.05 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company...


Zynerba Pharmaceuticals well-funded for its CBD clinical trials into 2021

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) CEO Armando Anido tells Proactive Investors the Pennsylvania-based biotech has $59.8 million to fund clinical trials for its cannabis-derived treatments 'beyond major milestones' into 2021. Zynerba is on track to report top-line results from tests...

on 03/12/2019

2 min read